The effect of dimethylbenz(a) anthracene on murine hematopoiesis.
DMBA was given p.o. to young adult female CBA/J mice in two regimens, a single dose of 1 mg and 4 doses of 1 mg in weekly intervals. In the peripheral blood only a transient reticulocytopenia and thrombocytopenia was observed in both groups. After 4 doses the thymus and spleen weights were reduced up to 4 weeks after the last dose. In the bone marrow the cellularity was lower in treated animals than in controls. After 1 mg DMBA pluripotent stem cells (CFUc) in the marrow were reduced to about 50--70% over a 2- to 3-week period, in the spleen the CFUs concentration was reduced to 10% at day 3 with about normal levels after 3  to 4 weeks. The compartment of granulocytic committed stem cells (CFUs) in both organs followed the same pattern with an overshoot in CFUc concentration in the spleen after 3 to 4 weeks. After 4 doses CFUs and CFUc were more depressed, regeneration began about 2 weeks after the last dose in both organs. CFUc in the marrow had normal and in the spleen supra-normal concentrations 3 and 4 weeks after the last dose.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D001551:Benz(a)Anthracenes / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D051379:Mice; D012156:Reticulocytes / Q000187:drug effects; D013154:Spleen / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced; D013950:Thymus Gland / Q000187:drug effects
D001551:Benz(a)Anthracenes; D015127:9,10-Dimethyl-1,2-benzanthracene